Beijing Defengrui Biological Technology

Beijing Defengrui Biological Technology is a Chinese biotechnology company specializing in the development and industrialization of innovative biopharmaceuticals, including recombinant protein vaccines and therapeutic proteins. The company is best known for its advanced pipeline in the HPV vaccine space, notably developing a high-valency 14-valent HPV vaccine candidate that is currently in Phase 3 clinical trials. Additionally, Defengrui focuses on the production of recombinant human serum albumin and other blood product substitutes using proprietary expression systems. Headquartered in Beijing, the firm leverages strong R&D capabilities to address significant public health needs in oncology and infectious diseases.